# Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

> **NCT03713632** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 545 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03713632
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-25
- **Primary completion:** 2021-09-23
- **Final completion:** 2022-07-19
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03713632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03713632, "Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03713632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*